Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel for Relapsed Metastatic Gastroesophageal Adenocarcinomas
NCT01365130Phase 2Terminated
- Start
- Jun 2011
- Primary completion
- Dec 2012
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel ginsenoside liposome injection in gastric adenocarcinoma and esophageal adenocarcinoma (EAC). Primary endpoint: Number of Patients Without Progression at 3 Months. Started Jun 2011; status: terminated.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT01365130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01365130.